%0 Journal Article
%A Rubio-Manzanares Dorado, Mercedes
%A Marín Gómez, Luis Miguel
%A Aparicio Sánchez, Daniel
%A Pereira Arenas, Sheila
%A Praena-Fernández, Juan Manuel
%A Borrero Martín, Juan Jose
%A Farfán López, Francisco
%A Gómez Bravo, Miguel Ángel
%A Muntané Relat, Jordi
%A Padillo Ruiz, Javier
%T Translational pancreatic cancer research: A comparative study on patient-derived xenograft models.
%D 2018
%U http://hdl.handle.net/10668/12166
%X To assess the viability of orthotopic and heterotopic patient-derived pancreatic cancer xenografts implanted into nude mice. This study presents a prospective experimental analytical follow-up of the development of tumours in mice upon implantation of human pancreatic adenocarcinoma samples. Specimens were obtained surgically from patients with a pathological diagnosis of pancreatic adenocarcinoma. Tumour samples from pancreatic cancer patients were transplanted into nude mice in three different locations (intraperitoneal, subcutaneous and pancreatic). Histological analysis (haematoxylin-eosin and Masson's trichrome staining) and immunohistochemical assessment of apoptosis (TUNEL), proliferation (Ki-67), angiogenesis (CD31) and fibrogenesis (α-SMA) were performed. When a tumour xenograft reached the target size, it was re-implanted in a new nude mouse. Three sequential tumour xenograft generations were generated (F1, F2 and F3). The overall tumour engraftment rate was 61.1%. The subcutaneous model was most effective in terms of tissue growth (69.9%), followed by intraperitoneal (57.6%) and pancreatic (55%) models. Tumour development was faster in the subcutaneous model (17.7 ± 2.6 wk) compared with the pancreatic (23.1 ± 2.3 wk) and intraperitoneal (25.0 ± 2.7 wk) models (P = 0.064). There was a progressive increase in the tumour engraftment rate over successive generations for all three models (F1 28.1% vs F2 71.4% vs F3 80.9%, P  In our experience, the faster development and greatest number of viable xenografts could make the subcutaneous model the best option for experimentation in pancreatic cancer.
%K Animal model
%K Immunohistological analysis
%K Nude mice
%K Pancreatic cancer
%K Patient-derived xenograft
%~